文献速递其他结缔组织病

磷脂酰肌醇3-激酶δ通路:干燥综合征的新治疗靶点

Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome.
PubMed 文献 · Ann Rheum Dis · 2018-11-24

研究探讨PI3Kδ通路在原发性干燥综合征(pSS)中的激活状态及抑制该通路的功能后果。在pSS唾液腺中检测到PI3Kδ下游介质pS6显著表达,并与T/B细胞标志物及CD138+浆细胞共定位;在小鼠局灶性涎腺炎模型中,PI3Kδ选择性抑制剂seletalisib在预防和治疗方案中均减少腺体内淋巴细胞和浆细胞聚集,并显著影响淋巴趋化因子/细胞因子产生、唾液流率和自身抗体生成。结论支持探索PI3Kδ通路抑制在pSS中的治疗潜力。

要点

  • pSS唾液腺中PI3Kδ通路下游pS6显著表达,并与T/B细胞及浆细胞共定位。
  • seletalisib在鼠局灶性涎腺炎模型中减少腺体淋巴细胞和浆细胞聚集。
  • seletalisib显著影响唾液流率和自身抗体产生。

核心结论

  • pSS患者腺体内存在PI3Kδ通路激活,且该通路在疾病模型中参与发病机制,支持探索其抑制作为pSS治疗策略。

研究设计与样本

  • 靶点验证实验检测pSS唾液腺中pS6表达与分布。
  • 在模拟pSS部分特征的鼠局灶性涎腺炎模型中,用PI3Kδ选择性抑制剂seletalisib进行体内阻断,分预防和治疗方案评估。

主要发现

  • pSS唾液腺中pS6显著表达,并与T/B细胞标志物及浸润腺体的CD138+浆细胞共定位。
  • seletalisib在预防和治疗方案中均减少鼠腺体内淋巴细胞和浆细胞积聚。
  • seletalisib显著影响与异位淋巴新生相关的淋巴趋化因子和细胞因子产生。
  • seletalisib显著影响唾液流率和自身抗体产生。

临床怎么用

  • 现有数据支持在pSS中进一步临床探索PI3Kδ通路抑制的治疗潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The phosphatidylinositol 3-kinase delta isoform (PI3Kδ) belongs to an intracellular lipid kinase family that regulate lymphocyte metabolism, survival, proliferation, apoptosis and migration and has been successfully targeted in B-cell malignancies. Primary Sjögren's syndrome (pSS) is a chronic immune-mediated inflammatory disease characterised by exocrine gland lymphocytic infiltration and B-cell hyperactivation which results in systemic manifestations, autoantibody production and loss of glandular function. Given the central role of B cells in pSS pathogenesis, we investigated PI3Kδ pathway activation in pSS and the functional consequences of blocking PI3Kδ in a murine model of focal sialoadenitis that mimics some features of pSS. METHODS AND RESULTS: Target validation assays showed significant expression of phosphorylated ribosomal protein S6 (pS6), a downstream mediator of the phosphatidylinositol 3-kinase delta (PI3Kδ) pathway, within pSS salivary glands. pS6 distribution was found to co-localise with T/B cell markers within pSS aggregates and the CD138+ plasma cells infiltrating the glands. In vivo blockade of PI3Kδ activity with seletalisib, a PI3Kδ-selective inhibitor, in a murine model of focal sialoadenitis decreased accumulation of lymphocytes and plasma cells within the glands of treated mice in the prophylactic and therapeutic regimes. Additionally, production of lymphoid chemokines and cytokines associated with ectopic lymphoneogenesis and, remarkably, saliva flow and autoantibody production, were significantly affected by treatment with seletalisib. CONCLUSION: These data demonstrate activation of PI3Kδ pathway within the glands of patients with pSS and its contribution to disease pathogenesis in a model of disease, supporting the exploration of the therapeutic potential of PI3Kδ pathway inhibition in this condition.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Nayar S, Campos J, Smith CG, et al. Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome. Ann Rheum Dis. 2018. PMID: 30472652. doi:10.1136/annrheumdis-2017-212619

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。